Urine Proteomics in SLE with Dr. Michelle Petri Dr. Michelle Petri discusses abstract 0536, Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria, being presented Saturday at #ACR22. https://t.co/rBDnbSqQCI https://t.co/WfERf1k5VB

• https://bit.ly/3UUdey4

Clinical Year in Review | Presented by Dr. Carol Langford at #ACR22 🌟 Review the Most Important Clinical Research Studies in the Past Year in #Rheumatology! 💫 https://t.co/Ao11xX1bYt

Preventing #rheumatoid #arthritis - the holy grail! STOPRA RCT of strong ACPA+; CCP3 high titre. No inflammatory arthritis. RCT of #Hydroxychloroquine vs placebo, N=142 Pts. At 3 yrs NO DIFF in onset@of RA in each group. identical curves. Abst1604 #ACR22 #ACRBest @RheumNow Darn! https://t.co/bEgbkxGSR4

#ACRBest Abstracts - Day 2 Day two at #ACR22 was full of great sessions on imaging, vasculitis, lupus, vasculitis, spondyloarthritis, COVID, pregnancy, microbiome, economics and more. Here are the RheumNow faculty selections for today. https://t.co/lAG1v2dHKQ https://t.co/oAG6zE7QzX

• https://bit.ly/3WY4yIO

Pike M Abstract 1113. Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a 24‑Week Placebo-controlled Proof-of-Concept Study #ACRBest #ACR22 @RheumNow

Most VEXAS pts have pulm involvement on HRCT. Pulmonary manifestations of VEXAS are nonspecific and characterized predominantly by inflammatory parenchymal involvement. Abs 1569 #ACR22 @RheumNow https://t.co/7AB3b9e7Lt https://t.co/ikhQMEu5GA

• Lung Involvement in VEXAS Syndrome - ACR Meeting Abstracts

Sarilumab demonstrated efficacy in difficult to treat GC resistant PMR patients. Abs 1543 #ACR22 @RheumNow https://t.co/TCo5g5i1qh https://t.co/tZOhvvuhpY

• Resolution of PMR Signs and Symptoms in Patients Treated with Sarilumab: A Phas…

Does lifestyle impact Tx. response? #Abstr 1510 looked at effect of lifestyle on TNFi response in #axSpA - The study found higher BMI (obese, overweight) and smoking were less likely to respond to TNFi - Important to discuss lifestyle when starting tx. @RheumNow #ACR22 https://t.co/z98DFMLxu3

Refractory cystoid macular edema assoc'd w/ Bechet's uveitis can be effectively treated either with ADA, IFX or TCZ. Abs 1564 #ACR22 @RheumNow https://t.co/WcEI4d0Cl5 https://t.co/Tk0T41coog

• Anti-TNF versus Anti-IL6 Receptor Antagonist Therapy in Severe Ocular Involveme…

ACR2022 Topic Panels https://t.co/0cto8DE7P5

• https://twitter.com/i/broadcasts/1rmxPkwQjyMJN